BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
25.48
+2.07 (8.84%)
Nov 1, 2024, 4:00 PM EDT - Market closed

BridgeBio Pharma Statistics

Total Valuation

BBIO has a market cap or net worth of $4.79 billion. The enterprise value is $6.08 billion.

Market Cap 4.79B
Enterprise Value 6.08B

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024, before market open.

Earnings Date Nov 12, 2024
Ex-Dividend Date n/a

Share Statistics

BBIO has 188.03 million shares outstanding. The number of shares has increased by 15.32% in one year.

Shares Outstanding 188.03M
Shares Change (YoY) +15.32%
Shares Change (QoQ) +4.97%
Owned by Insiders (%) 5.38%
Owned by Institutions (%) 66.39%
Float 127.53M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 20.47
Forward PS 15.13
PB Ratio n/a
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 27.76
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.59

Current Ratio 4.59
Quick Ratio 3.34
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -5.78

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -48.44%
Return on Capital (ROIC) -60.97%
Revenue Per Employee $394,108
Profits Per Employee -$816,221
Employee Count 556
Asset Turnover 0.34
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -2.15% in the last 52 weeks. The beta is 1.09, so BBIO's price volatility has been similar to the market average.

Beta (5Y) 1.09
52-Week Price Change -2.15%
50-Day Moving Average 25.95
200-Day Moving Average 28.07
Relative Strength Index (RSI) 52.81
Average Volume (20 Days) 1,533,604

Short Selling Information

The latest short interest is 17.78 million, so 9.46% of the outstanding shares have been sold short.

Short Interest 17.78M
Short Previous Month 18.63M
Short % of Shares Out 9.46%
Short % of Float 13.94%
Short Ratio (days to cover) 8.60

Income Statement

In the last 12 months, BBIO had revenue of $219.12 million and -$453.82 million in losses. Loss per share was -$2.58.

Revenue 219.12M
Gross Profit 216.73M
Operating Income -502.99M
Pretax Income -453.82M
Net Income -453.82M
EBITDA -496.59M
EBIT -502.99M
Loss Per Share -$2.58
Full Income Statement

Balance Sheet

The company has $447.77 million in cash and $1.73 billion in debt, giving a net cash position of -$1.28 billion or -$6.82 per share.

Cash & Cash Equivalents 447.77M
Total Debt 1.73B
Net Cash -1.28B
Net Cash Per Share -$6.82
Equity (Book Value) -1.08B
Book Value Per Share -5.81
Working Capital 481.87M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$414.88 million and capital expenditures -$1.62 million, giving a free cash flow of -$416.49 million.

Operating Cash Flow -414.88M
Capital Expenditures -1.62M
Free Cash Flow -416.49M
FCF Per Share -$2.22
Full Cash Flow Statement

Margins

Gross margin is 98.91%, with operating and profit margins of -229.54% and -207.11%.

Gross Margin 98.91%
Operating Margin -229.54%
Pretax Margin -210.62%
Profit Margin -207.11%
EBITDA Margin -226.63%
EBIT Margin -229.54%
FCF Margin -190.07%

Dividends & Yields

BBIO does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -15.32%
Shareholder Yield -15.32%
Earnings Yield -9.47%
FCF Yield -8.69%
Dividend Details

Analyst Forecast

The average price target for BBIO is $46.83, which is 83.79% higher than the current price. The consensus rating is "Strong Buy".

Price Target $46.83
Price Target Difference 83.79%
Analyst Consensus Strong Buy
Analyst Count 13
Revenue Growth Forecast (5Y) 189.20%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

BBIO has an Altman Z-Score of -4.13 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -4.13
Piotroski F-Score 5